Altered death receptor signaling promotes epithelial-to-mesenchymal transition and acquired chemoresistance

Scientific Reports

Volumn 2, Issue , 2012, Pages

  Antoon, James W ^a   Lai, Rongye ^b   Struckhoff, Amanda P ^a   Nitschke, Ashley M ^a   Elliott, Steven ^a   Martin, Elizabeth C ^a   Rhodes, Lyndsay V ^a   Yoon, Nam Seung ^b   Salvo, Virgilio A ^a   Shan, Bin ^a   Beckman, Barbara S ^a   Nephew, Kenneth P ^b   Burow, Matthew E ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEATH RECEPTOR; ESTROGEN RECEPTOR ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL; APOPTOSIS; ARTICLE; BREAST TUMOR; CELL SURVIVAL; CELL TRANSFORMATION; CLUSTER ANALYSIS; DISEASE MODEL; DRUG RESISTANCE; DRUG SCREENING; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MOUSE; NUDE MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CLUSTER ANALYSIS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; NF-KAPPA B; RECEPTORS, DEATH DOMAIN; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84864486088     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep00539     Document Type: Article

References (69)

1. American Cancer Society. v. (The Society, Atlanta, GA, 2011).
2. Seidman, A. D. Chemotherapy for advanced breast cancer: A current perspective. Seminars in oncology 23, 55-59 (1996).
3. Wang, G. H. et al. Bovine herpesvirus 4 BORFE2 protein inhibits Fas- and tumor necrosis factor receptor 1-induced apoptosis and contains death effector domains shared with other gamma-2 herpesviruses. J Virol 71, 8928-8932 (1997).
4. Baker, S. J. & Reddy, E. P. Modulation of life and death by the TNF receptor superfamily. Oncogene 17, 3261-3270 (1998).
5. Vandenabeele, P., Declercq, W., Beyaert, R. & Fiers, W. Two tumour necrosis factor receptors: structure and function. Trends Cell Biol 5, 392-399 (1995).
6. Boldin, M. P. et al. Self-Association of the "death domains" of the p55 tumor necrosis factor (TNF) receptor and Fas/APO1 prompts signaling for TNF and Fas/APO1 effects. J Biol Chem 270, 387-391 (1995).
7. Hsu, H., Xiong, J. & Goeddel, D. V. The TNF receptor 1-Associated protein TRADD signals cell death and NF-kappa B activation. Cell 81, 495-504 (1995).
8. Peraldi, P.,Hotamisligil, G. S., Buurman,W. A., White, M. F. & Spiegelman, B.M. Tumor necrosis factor (TNF)-Alpha inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphingomyelinase. The Journal of biological chemistry 271, 13018-13022 (1996).
9. Zyad, A., Benard, J., Tursz, T., Clarke, R. & Chouaib, S. Resistance to TNF-Alpha and adriamycin in the human breast cancer MCF-7 cell line: relationship to MDR1, MnSOD, and TNF gene expression. Cancer Res 54, 825-831 (1994).
10. Herrnring, C. et al. Expression of the apoptosis-inducing ligands FasL and TRAIL in malignant and benign human breast tumors. Histochem Cell Biol 113, 189-194 (2000).
11. Bebok, Z.,Markus, B. & Nemeth, P. Prognostic relevance of transforming growth factor alpha (TGF-Alpha) and tumor necrosis factor alpha (TNF-Alpha) detected in breast cancer tissues by immunohistochemistry. Breast Cancer Res Treat 29, 229-235 (1994).
12. Gaudet, M. M. et al. Genetic variation in tumor necrosis factor and lymphotoxinalpha (TNF-LTA) and breast cancer risk. Human genetics 121, 483-490 (2007).
13. de Jong, S., Timmer, T., Heijenbrok, F. J. & de Vries, E. G. Death receptor ligands, in particular TRAIL, to overcome drug resistance. Cancer metastasis reviews 20, 51-56 (2001).
14. LeBlanc, H. et al. Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nature medicine 8, 274-281 (2002).
15. Krajewski, S. et al. Prognostic significance of apoptosis regulators in breast cancer. Endocr Relat Cancer 6, 29-40 (1999).
16. Buchholz, T. A. et al. Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J 9, 33-41 (2003).
17. Wang, C. Y.,Mayo, M. W. & Baldwin, A. S., Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 274, 784-787 (1996).
18. Nakshatri, H. & Goulet, R. J., Jr. NF-kappaB and breast cancer. Curr Probl Cancer 26, 282-309 (2002).
19. Struckhoff, A. P. et al. Novel ceramide analogs as potential chemotherapeutic agents in breast cancer. J Pharmacol Exp Ther 309, 523-532 (2004).
20. Antoon, J. W., White, M. D., Burow, M. E. & Beckman, B. S. Dual inhibition of sphingosine kinase isoforms ablates TNF-induced drug resistance. Oncol Rep 27, 1779-1786 (2012).
21. Antoon, J. W. & Beckman, B. S. Sphingosine kinase: A promising cancer therapeutic target. Cancer Biol Ther 11, 647-650 (2011).
22. Antoon, J. W. et al. Targeting NFkB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. Cancer Biol Ther 11, 678- 689 (2011).
23. Chmura, S. J. et al. Loss of ceramide production confers resistance to radiationinduced apoptosis. Cancer research 57, 1270-1275 (1997).
24. Lucci, A., Han, T. Y., Liu, Y. Y., Giuliano, A. E. & Cabot, M. C. Multidrug resistance modulators and doxorubicin synergize to elevate ceramide levels and elicit apoptosis in drug-resistant cancer cells. Cancer 86, 300-311 (1999).
25. Weldon, C. B. et al. Sensitization of apoptotically-resistant breast carcinoma cells to TNF and TRAIL by inhibition of p38 mitogen-Activated protein kinase signaling. Int J Oncol 24, 1473-1480 (2004).
26. Chua, H. L. et al. NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene 26, 711-724 (2007).
27. Hayden, M. S. & Ghosh, S. Signaling to NF-kappaB. Genes & development 18, 2195-2224 (2004).
28. Cao, Y. & Karin, M. NF-kappaB in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia 8, 215-223 (2003).
29. Huber, M. A. et al. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in amodel of breast cancer progression. J Clin Invest 114, 569-581 (2004).
30. Kang, Y.&Massagué, J. Epithelial-mesenchymal transitions: Twist in development and metastasis. Cell 118, 277-279 (2004).
31. Nieto, M. A. The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol 3, 155-166 (2002).
32. Moreno-Bueno, G. et al. Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for Snail, Slug, and E47 factors in epithelialmesenchymal transition. Cancer Res 66, 9543-9556 (2006).
33. Al Saleh, S., Sharaf, L. H. & Luqmani, Y. A. Signalling pathways involved in endocrine resistance in breast cancer and associations with epithelial to mesenchymal transition (Review). Int J Oncol 38, 1197-1217 (2011).
34. Rubio, M. F. et al. TNF-Alpha enhances estrogen-induced cell proliferation of estrogen-dependent breast tumor cells through a complex containing nuclear factor-kappa B. Oncogene 25, 1367-1377 (2006).
35. Park, K. J., Krishnan, V., O'Malley, B. W., Yamamoto, Y. & Gaynor, R. B. Formation of an IKKalpha-dependent transcription complex is required for estrogen receptor-mediated gene activation. Mol Cell 18, 71-82 (2005).
36. Kerbel, R. S. Impact of multicellular resistance on the survival of solid tumors, including micrometastases. Invasion Metastasis 14, 50-60 (1994).
37. Burow, M. E. et al. Differences in susceptibility to tumor necrosis factor alphainduced apoptosis among MCF-7 breast cancer cell variants. Cancer Res 58, 4940-4946 (1998).
38. Meacham,W. D., Antoon, J.W., Burow,M. E., Struckhoff, A. P. & Beckman, B. S. Sphingolipids as determinants of apoptosis and chemoresistance in the MCF-7 cell model system. Exp Biol Med (Maywood) 234, 1253-1263 (2009).
39. Lee, S. H. & Nam, H. S. TNF alpha-induced down-regulation of estrogen receptor alpha in MCF-7 breast cancer cells. Molecules and cells 26, 285-290 (2008).
40. Ben-Porath, I. et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nature genetics 40, 499-507 (2008).
41. Gionet, N., Jansson,D., Mader, S.&Pratt, M. A. NF-kappaB and estrogen receptor alpha interactions: Differential function in estrogen receptor-negative and - positive hormone-independent breast cancer cells. Journal of cellular biochemistry 107, 448-459 (2009).
42. Qiu, J. et al. Toll-like receptor 9 agonist inhibits ERalpha-mediated transactivation by activating NF-kappaB in breast cancer cell lines. Oncol Rep 22, 935-941 (2009).
43. Biswas, D. K., Cruz, A. P., Gansberger, E.&Pardee, A. B. Epidermal growth factorinduced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America 97, 8542-8547 (2000).
44. Vesuna, F. et al. Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-Alpha. Oncogene (2011).
45. Kuroki, J. et al. Cell-permeable ceramide inhibits the growth of B lymphoma Raji cells lacking TNF-Alpha-receptors by inducing G0/G1 arrest but not apoptosis: A newmodel for dissecting cell-cycle arrest and apoptosis. Leukemia 10, 1950-1958 (1996).
46. Zyad, A., Branellec, D., Mahe, Y., Tursz, T. & Chouaib, S. The development of human tumor-cell resistance to TNF-Alpha does not confer resistance to cytokineinduced cellular cytotoxic mechanisms. Int J Cancer 52, 953-958 (1992).
47. Bratton, M. R. et al. GalphaO Potentiates Estrogen Receptor-Alpha Activity Via the Erk Signaling Pathway. J Endocrinol 214, 45-54 (2012).
48. Chang, F., Lacey, M. R., Bouljihad, M., Honer Zu Bentrup, K. & Fortgang, I. S. Tumor necrosis factor receptor 1 functions as a tumor suppressor. American journal of physiology. Gastrointestinal and liver physiology 302, G195-206 (2012).
49. Sasi, S. P. et al. Breaking the 'harmony' of TNF-Alpha signaling for cancer treatment. Oncogene (2011).
50. Charles, K. A. et al. The tumor-promoting actions of TNF-Alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest 119, 3011-3023 (2009).
51. Cai, Z. et al. Alteration of the sphingomyelin/ceramide pathway is associated with resistance of human breast carcinoma MCF7 cells to tumor necrosis factor-Alphamediated cytotoxicity. J Biol Chem 272, 6918-6926 (1997).
52. Grell, M. et al. Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: A role for TNF-R1 activation by endogenous membraneanchored TNF. Embo J 18, 3034-3043 (1999).
53. Rothe, M., Sarma, V.,Dixit, V. M.&Goeddel, D. V. TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40. Science 269, 1424-1427 (1995).
54. Van Antwerp, D. J., Martin, S. J., Kafri, T., Green, D. R. & Verma, I. M. Suppression of TNF-Alpha-induced apoptosis by NF-kappaB. Science 274, 787-789 (1996).
55. Nakshatri, H., Bhat-Nakshatri, P.,Martin, D. A., Goulet, R. J., Jr. & Sledge, G. W., Jr. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Molecular and cellular biology 17, 3629-3639 (1997).
56. Uetsuka, H. et al. Inhibition of inducible NF-kappaB activity reduces chemoresistance to 5-fluorouracil in human stomach cancer cell line. Exp Cell Res 289, 27-35 (2003).
57. Wang, C. Y., Cusack, J. C., Jr., Liu, R. & Baldwin, A. S., Jr. Control of inducible chemoresistance: enhanced anti-Tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nature medicine 5, 412-417 (1999).
58. Xue, C., Plieth, D., Venkov, C., Xu, C. & Neilson, E. G. The gatekeeper effect of epithelial-mesenchymal transition regulates the frequency of breast cancer metastasis. Cancer research 63, 3386-3394 (2003).
59. Kerbel, R. S., Kobayashi, H. & Graham, C. H. Intrinsic or acquired drug resistance and metastasis: Are they linked phenotypes? Journal of cellular biochemistry 56, 37-47 (1994).
60. Lou, Y. et al. Epithelial-mesenchymal transition (EMT) is not sufficient for spontaneous murine breast cancer metastasis. Developmental dynamics : An official publication of the American Association of Anatomists 237, 2755-2768 (2008).
61. Antoon, J. W. et al. Targeting NF-kB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. Cancer biology&therapy 11, 678-689 (2011).
62. Antoon, J. W. et al. Design, synthesis, and biological activity of a family of novel ceramide analogues in chemoresistant breast cancer cells. J Med Chem 52, 5748-5752 (2009).
63. Antoon, J.W. et al. Novel D: -erythro N-octanoyl sphingosine analogs as chemoand endocrine-resistant breast cancer therapeutics. Cancer Chemother Pharmacol 65, 1191-1195 (2010).
64. Salvo, V. A. et al. Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesis. Clin Cancer Res 12, 7159-7164 (2006).
65. Boue, S. M. et al. Identification of the potent phytoestrogen glycinol in elicited soybean (Glycine max). Endocrinology 150, 2446-2453 (2009).
66. Rhodes, L. V. et al. Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence. Breast Cancer Res Treat 121, 293-300 (2010).
67. Schmittgen, T. D. et al. Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: comparison of endpoint and real-Time methods. Analytical biochemistry 285, 194-204 (2000).
68. Zhou, C. et al. Proteomic analysis of tumor necrosis factor-Alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype. Breast cancer research : BCR 10, R105 (2008).
69. Fan, M. et al. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer research 66, 11954-11966 (2006).